AstraZeneca, Daiichi Sankyo's Enhertu gets approval in Canada for breast cancer subtype

Jun. 23, 2022 8:28 AM ETAstraZeneca PLC (AZN), SKYF, DSNKYBy: Ravikash, SA News Editor

AstraZeneca production plant

Roland Magnusson/iStock Editorial via Getty Images

  • Health Canada approved the expanded use of AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat certain patients with breast cancer.
  • Enhertu (trastuzumab deruxtecan) can now be used to treat adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and whose disease recurrence during or within six months of completing neoadjuvant or adjuvant therapy.
  • The approval was backed by data from a phase 3 trial, dubbed DESTINY-Breast03, which showed Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine.
  • The drug was approved for use for this particular indication in the U.S. in May.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.